STAGE IVA PROSTATE CANCER AJCC V8

This study tests whether a shorter course of higher-dose radiation (hypofractionated) works as well as or better than the standard longer course for men with prostate cancer who have had their prostate removed. About 186 men will be randomly assigned to one of the two radiation s…

This study looks at whether men with metastatic prostate cancer that responds extremely well to hormone therapy can safely take a break from treatment. The goal is to see if their testosterone levels can recover and how long they can stay off therapy without the cancer worsening.…

This early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…

This phase 2 trial tests a combination of abiraterone, prednisone, and apalutamide in 60 men with hormone-naive prostate cancer that has spread. The goal is to see how long patients can stay on treatment and how well it controls the cancer. Participants must have high-risk featur…

This study tests whether men with high-risk prostate cancer can receive treatment tailored to their genetic risk score. Those with a low genetic risk may get a shorter course of hormone therapy (12 months instead of 24) plus radiation, while those with a high genetic risk get an …

This study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other drugs and radiation in people with advanced cancers that have not responded to standard treatments. About 173 adults with various solid tumors, including prostate cancer, will re…